STAAR Surgical (STAA)
| Bid | 16.5 |
| Market Cap | 846.4M |
| Revenue (ttm) | 279.13M |
| Net Income (ttm) | -71.08M |
| EPS (ttm) | -1.44 |
| PE Ratio (ttm) | -11.87 |
| Forward PE | 62.43 |
| Analyst | Hold |
| Ask | 17.74 |
| Volume | 484,334 |
| Avg. Volume (20D) | 918,053 |
| Open | 17.05 |
| Previous Close | 17.44 |
| Day's Range | 16.94 - 17.45 |
| 52-Week Range | 13.50 - 49.86 |
| Beta | 0.61 |
About STAA
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for STAA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 weeks ago · businesswire.com
STAAR Surgical Announces Participation in Upcoming Investor ConferencesLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
4 weeks ago · businesswire.com
STAAR Surgical Announces $30 Million Share Repurchase AuthorizationLAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
1 month ago · seekingalpha.com
STAAR Surgical Q1: Clouded Outlook Warrants Caution (Rating Downgrade)Sales in China were severely impacted due to inventory de-stocking, but the outlook for the region for H2 2025 looks promising. Global sales ex-China were weak, with management choosing to withdraw th...
